BUSINESS ACQUISITIONS ChanTest In October 2014, the Company acquired ChanTest Corporation (ChanTest), a leading provider of ion channel testing services to the pharmaceutical and biotech industry. The acquisition augments the Company s early discovery capabilities and enhances the Company s ability to support clients  target discovery and lead optimization efforts. The preliminary purchase price of the acquisition was $59.3 million , including $0.3 million in contingent consideration. The aggregate, undiscounted amount of contingent consideration that could become payable is a maximum of $2.0 million . The Company estimated the fair value of this contingent consideration based on a probability-weighted set of outcomes. The purchase price is subject to an adjustment based on the final determined net working capital as of the closing date. The business is reported in the Company s Discovery and Safety Assessment (DSA) reportable segment. The preliminary purchase price allocation of $52.1 million , net of $7.2 million in cash acquired, is as follows: October 29, 2014 (in thousands) Current assets (excluding cash) 4,648 Property, plant and equipment 1,579 Definite-lived intangible assets 23,920 Goodwill 34,927 Current liabilities (3,515 ) Long-term liabilities (9,486 ) Total purchase price allocation $ 52,073 The purchase price allocations were prepared on a preliminary basis and are subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed. During the three months ended March 28, 2015 , the Company recorded measurement period adjustments related to the ChanTest acquisition that resulted in an immaterial change to the purchase price allocation. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. The breakout of definite-lived intangible assets acquired is as follows: October 29, 2014 Weighted average amortization life (in thousa